Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Core operating profit and margin 47.2% 46.2% % of sales 44.1% 40.2% 37.9% 39.2% +2.3%p¹ +1.4%p¹ +9%¹ CHFM 12,668 +8%¹ 11,766 11,652 10,961 10,318 9,562 1 At CER-Constant Exchange Rates 2020 2021 2022 Roche Group Pharma Division 16.8% 25.7% 25.7% 0.0%p¹ +11%¹ 2,324 2,560 1,022 Diagnostics Division Roche 58

View entire presentation